Osmetech Aims to Raise $40M in US IPO

Osmetech also reported that sales during full-year 2009 rose 81 percent mostly on the strength of its array-based tests. The company said net loss during the 12-month period narrowed 16 percent year over year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.